SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
senate help committee
New Report Shows Working-Class Americans Live 7 Years Fewer Than Rich
"The massive income and wealth inequality that exists in America today is not just an economic issue, it is literally a matter of life and death," said Sen. Bernie Sanders of Vermont.
Mar 07, 2025
People living in the top 1% of U.S. counties ranked by median household income live on average seven years longer than their counterparts in the bottom 50% of counties, according to a Friday report from Sen. Bernie Sanders, an Independent representing Vermont and the ranking member of the Senate Committee on Health, Education, Labor, and Pensions.
"The massive income and wealth inequality that exists in America today is not just an economic issue, it is literally a matter of life and death," said Sanders in a Friday statement announcing the report.
What's more, the stress of living paycheck to paycheck "also leads to higher levels of anxiety, depression, cardiovascular disease and poor health," Sanders argued, in a nod to some of the survey responses included in the analysis.
The analysis echoes findings by other researchers that higher income is associated with greater longevity. According to a Congressional Research Service report from 2021, life expectancy has generally increased over time in the United States—with the exception of during Covid-19 pandemic—but "researchers have long documented that it is lower for individuals with lower socioeconomic status compared with individuals with higher socioeconomic status. Recent studies provide evidence that this gap has widened in recent decades."
The findings in Sanders' report relied on county-level data in the United States between 2015 and 2019, the five years prior to the pandemic. For that time period, Sanders' staff matched each U.S. county with both median household income data from the U.S. Census Bureau and average life expectancy data from the Institute for Health Metrics and Evaluation, according to the report.
The life expectancy gap was greater when comparing higher-earning urban and suburban communities with lower-earning rural communities. "Urban and suburban counties with a median household income of $100,000 have an average life expectancy of 81.6 years, while small rural counties with a median household income of $30,000 have an average life expectancy of 71.7 years—a 10-year gap," according to the report.
A boost in earnings also translated into a boost in life expectancy. For example, "among rural counties, a $10,000 increase in median annual household income is associated with an additional 2.6 years of life expectancy," according to the report.
The analysis also includes qualitative data collected by Sanders, who asked working people via social media survey how stress impacts their lives. The outreach generated over 1,000 responses from people around the country.
According to the report, Caitlin from Colorado said: "Stress isn't just an inconvenience for me—it's a direct threat to my heart. Living with a congenital heart defect and multiple mechanical valves means that every surge of anxiety, every sleepless night worrying about bills, isn't just mentally exhausting—it physically wears on my heart."
"Living paycheck to paycheck while supporting a family stresses me out. We are always just one financial emergency from being homeless," said Patrick from Missouri.
One person also reported having to go without preventative healthcare because they are between jobs and can't afford the care without insurance.
The report offers a number of policy solutions to address the key findings of the analysis, including raising the minimum wage to at least $17 an hour, guaranteeing paid family and medical leave, and passing Medicare for All, which would enact a single-payer health insurance program.
Keep ReadingShow Less
Sanders Says Senate Should Probe DOGE and Subpoena Musk
"My constituents in Vermont and constituents all over this country want to know what the hell is going on with the federal government right now," the democratic socialist senator said.
Mar 06, 2025
Sen. Bernie Sanders (I-Vt.)—the ranking member of the Senate Committee on Health, Education, Labor, and Pensions—on Thursday urged the panel to launch an investigation into the Department of Government Efficiency and its de facto chief, Elon Musk, "the richest man in the world, to testify about his plans for running the federal government."
"I think everybody on this committee and the people of America understand who is running the government, and it's not going to be the secretary of labor," Sanders said during Thursday's HELP committee hearing on the confirmation of Keith Sonderling, Republican U.S. President Donald Trump's nominee for deputy labor secretary.
"We must find out what is going on in the federal government. And the way we do that is bringing Mr. Musk before this committee."
"With all due respect to President Trump's nominees, the... person who is running the government right now is Elon Musk," Sanders asserted.
"Mr. Musk has taken it upon himself, with the support of President Trump, to virtually dismantle the United States government," the senator said.
Sanders noted various attacks on agencies, including efforts to oust over 80,000 employees at the Department of Veterans Affairs and get rid of half of the Social Security Administration's employees, "at a time when Social Security is now grossly understaffed."
"Mr. Musk has ordered [the Department of Health and Human Services], the Department of Labor, and the Department of Education to fire employees, hand over confidential and sensitive data, and defy judicial orders," he added.
"My constituents in Vermont and constituents all over this country want to know what the hell is going on with the federal government right now," Sanders said. "And it's not going to be the next deputy secretary of labor who is going to tell them."
"So if we are serious... about our oversight responsibilities, we must find out what is going on in the federal government," he added. "And the way we do that is bringing Mr. Musk before this committee."
Sanders' call for an investigation into DOGE and subpoena for Musk came on the same day that Trump convened an in-person Cabinet meeting during which he clarified that the department secretaries are in charge of their agencies, not Musk. Multiple administration officials toldPolitico that "Musk was empowered to make recommendations to the departments but not to issue unilateral decisions on staffing and policy."
Musk was in the room for the meeting. As Politico reported:
The president's message represents the first significant move to narrow Musk's mandate. According to Trump's new guidance, DOGE and its staff should play an advisory role—but Cabinet secretaries should make final decisions on personnel, policy, and the pacing of implementation.
Musk joined the conversation and indicated he was on board with Trump's directive. According to one person familiar with the meeting, Musk acknowledged that DOGE had made some missteps—a message he shared earlier this week with members of Congress.
"As the secretaries learn about, and understand, the people working for the various departments, they can be very precise as to who will remain, and who will go," Trump later explained on his Truth Social platform. "We say the 'scalpel' rather than the 'hatchet.' The combination of them, Elon, DOGE, and other great people will be able to do things at a historic level."
Since its launch, DOGE has been plagued by statistical and accounting mistakes, as well as overzealous and errant firings of thousands of critical government workers, including people in charge of nuclear and air traffic safety and pandemic response.
Keep ReadingShow Less
Sanders Calls BS on Novo Nordisk Excuses for Sky-High Prices of Ozempic, Wegovy
During a hearing, Sen. Bernie Sanders told the pharmaceutical giant's CEO to "stop ripping us off."
Sep 24, 2024
Sen. Bernie Sanders on Tuesday rejected the pharmaceutical Novo Nordisk's justifications for the high prices of two increasingly popular obesity and diabetes medications in the United States, telling the company's CEO to "stop ripping us off."
Sanders' (I-Vt.) remarks came during a Senate Health, Education, Labor, and Pensions (HELP) Committee hearing featuring testimony from Lars Fruergaard Jørgensen, the chief executive of the Danish pharmaceutical giant Novo Nordisk.
"The United States is Novo Nordisk's cash cow for Ozempic and Wegovy," said Sanders, noting that the company has made $50 billion in sales of the two drugs since 2018—a majority of them in the U.S., where the company charges significantly higher prices than in Denmark, Germany, and other rich countries.
The senator rejected Jørgensen's efforts in his written testimony to explain away the high prices for the two medications. The executive pointed to the "complexity" of the U.S. healthcare system and rebates to pharmacy benefit managers (PBMs), among other factors, to justify the current list prices of Ozempic and Wegovy—$969 a month and $1,349 a month, respectively, in the U.S.
Sanders observed that "even factoring in all of the rebates that PBMs receive, the net price for Ozempic is still nearly $600—over nine times as much as it costs in Germany."
"And the estimated net price of Wegovy," the senator added, "is over $800—nearly four and a half times as much as it costs in Denmark."
Watch the full hearing:
Ahead of Tuesday's hearing, Sanders released a report countering Jørgensen's insistence that cutting the list prices of Ozempic and Wegovy would lead to PBMs "dropping" the medications from their formularies, resulting in less access to the drugs.
"Three major PBMs that help determine drug coverage for most of the nation—Cigna Group/Express Scripts, CVS Health/Caremark, UnitedHealth Group/Optum Rx—confirmed to Chair Sanders that a list price reduction would not negatively impact formulary placement for Ozempic and Wegovy, and affirmed that lower list prices would, in fact, make the drugs more widely available to patients in need," Sanders' office said.
The report also disputes Novo Nordisk's claim that price cuts would undermine the company's ability to "invest in new and innovative drug research and development efforts"—a claim that pharmaceutical firms often use to justify high prices.
"Since launching Ozempic in 2018, Novo Nordisk has spent twice as much on stock buybacks and dividends ($44 billion) as it has on research and development ($21 billion), according to financial filings," the report notes. "Novo Nordisk has also lavished cash and perks on healthcare providers, sending doctors on trips to Alaska, Hawaii, and Florida, and paying for nearly 1.7 million meals and snacks for doctors and other healthcare providers to promote Ozempic and Wegovy, federal records show."
"Right now, rationing is a painful reality for American patients dealing with issues related to diabetes and obesity."
During Tuesday's hearing, Jørgensen said he would be willing to do "anything that will help patients get access to affordable medicine" but did not specifically pledge to reduce the prices of Ozempic and Wegovy. Jørgensen told the Senate committee that PBMs' vows not to reduce access to the drugs in the case of price cuts was "new information to me."
The consumer advocacy group Public Citizensaid following the Senate hearing that Medicare would save $14 billion on Ozempic and Wegovy if the Biden administration used its existing legal authority to approve generic competition for the two medications.
"Novo today appeared unable, or unwilling, to articulate a credible response [to] why it charges Americans more than people in other wealthy countries," said Peter Maybarduk, director of Public Citizen's Access to Medicines program. "The federal government must open generic competition with Ozempic and Wegovy."
"Right now, rationing is a painful reality for American patients dealing with issues related to diabetes and obesity," he continued. "The federal government has an obligation to serve these patients' health needs. In doing so, we can also improve Medicare's financial health. As Sen. Sanders has cautioned, Novo Nordisk's price gouging practices would impose unmanageable costs on Medicare if its drugs were made available to all seniors who might benefit from them."
Keep ReadingShow Less
Most Popular